SELLAS Life Sciences Group
SELLAS Life Sciences Group is a late-stage biopharmaceutical company dedicated to developing innovative cancer immunotherapies targeting various malignancies. The company’s lead product candidate, galinpepimut-S, is a peptide immunotherapy that specifically targets the Wilms Tumor 1 (WT1) antigen, which is prevalent in many cancers. Traditional treatment methods have struggled to effectively address the WT1 protein, making this therapy significant in the field of cancer treatment. SELLAS is advancing multiple clinical trials, including pivotal Phase III studies for acute myeloid leukemia and malignant pleural mesothelioma, as well as ongoing Phase I and II studies for ovarian cancer and multiple myeloma. Positive preliminary results have indicated improved survival rates compared to standard treatments. The company has received orphan and fast track designations from the US FDA, highlighting the potential of galinpepimut-S to enhance existing therapies by targeting residual cancer cells and maintaining immune surveillance. Additionally, SELLAS is developing GFH009, a selective small molecule inhibitor aimed at cyclin-dependent kinase 9, further expanding its portfolio in cancer therapeutics.
SELLAS Life Sciences Group
Acquisition in 2017
SELLAS Life Sciences Group is a late-stage biopharmaceutical company dedicated to developing innovative cancer immunotherapies targeting various malignancies. The company’s lead product candidate, galinpepimut-S, is a peptide immunotherapy that specifically targets the Wilms Tumor 1 (WT1) antigen, which is prevalent in many cancers. Traditional treatment methods have struggled to effectively address the WT1 protein, making this therapy significant in the field of cancer treatment. SELLAS is advancing multiple clinical trials, including pivotal Phase III studies for acute myeloid leukemia and malignant pleural mesothelioma, as well as ongoing Phase I and II studies for ovarian cancer and multiple myeloma. Positive preliminary results have indicated improved survival rates compared to standard treatments. The company has received orphan and fast track designations from the US FDA, highlighting the potential of galinpepimut-S to enhance existing therapies by targeting residual cancer cells and maintaining immune surveillance. Additionally, SELLAS is developing GFH009, a selective small molecule inhibitor aimed at cyclin-dependent kinase 9, further expanding its portfolio in cancer therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.